Sounds very interesting. Is this a directed differentiation approach and do you have any issues with off target differentiation?

What hurdles do you need to overcome if you do manage to produce on a scale to introduce this as a therapeutic option (e.g. regulatory)? Is the risk of mycoplasma contamination a concern in culturing this for use?